Allscripts, a Chicago, Illinois-based healthcare information technology solution provider, as per recent reports last week, has announced its plans to acquire ZappRx, a Boston, Massachusetts-based prescription, and prior authorization platform. With this acquisition, Allscripts plans to expand its business offerings beyond the electronic health record (EHR).
ZappRx, founded in 2012 by Zoe Barry, has, to date, raised $40 million in total funding. The company streamlines the complex and sophisticated process to order specialty medications, which further offers increased efficiencies when it comes to collecting and maintaining the associated myriad requisite information for ordering specialty drugs, i.e. pharmacy information, payer/prior authorization requirements, and relevant clinical history.
This streamlining enables providers, pharmacists, and payers to digitally interact with one another seamlessly to fill in a prescription, thus limiting the need to fax clinical details or make phone calls to a bare minimum. The ZappRx platform currently is live in Pulmonary (including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Idiopathic Pulmonary Fibrosis (IPF)), Severe Asthma, Cardiology (including Hyperlipidemia and Congestive Heart Failure), and Gastroenterology (including Crohn’s Disease and Ulcerative Colitis).
In a statement, Allscripts said, “Allscripts is excited to add ZappRx’s platform to our growing portfolio. The specialty-prescribing space is a key focus area for Veradigm, our payer and life sciences business unit. While we cannot share the details of our agreement publicly, the addition of ZappRx’s team and technology will augment our solution offerings and provide great value to our clients.